NZ631049A - Methods of treating lactose intolerance - Google Patents
Methods of treating lactose intoleranceInfo
- Publication number
- NZ631049A NZ631049A NZ631049A NZ63104913A NZ631049A NZ 631049 A NZ631049 A NZ 631049A NZ 631049 A NZ631049 A NZ 631049A NZ 63104913 A NZ63104913 A NZ 63104913A NZ 631049 A NZ631049 A NZ 631049A
- Authority
- NZ
- New Zealand
- Prior art keywords
- lactose intolerance
- methods
- treating lactose
- ppar
- agonists
- Prior art date
Links
- 201000010538 Lactose Intolerance Diseases 0.000 title abstract 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 4
- 239000000556 agonist Substances 0.000 abstract 3
- QLJYLJGYIDIJPT-SECBINFHSA-N (2r)-3-(4-aminophenyl)-2-methoxypropanoic acid Chemical compound CO[C@@H](C(O)=O)CC1=CC=C(N)C=C1 QLJYLJGYIDIJPT-SECBINFHSA-N 0.000 abstract 1
- KKDAZKGSLSSFFB-UHFFFAOYSA-N 5-[di(propan-2-yl)amino]-2-hydroxybenzoic acid Chemical compound CC(C)N(C(C)C)C1=CC=C(O)C(C(O)=O)=C1 KKDAZKGSLSSFFB-UHFFFAOYSA-N 0.000 abstract 1
- 206010023648 Lactase deficiency Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C13/00—Cream; Cream preparations; Making thereof
- A23C13/12—Cream preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/09—Other cheese preparations; Mixtures of cheese with other foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/08—Whey; Whey preparations containing other organic additives, e.g. vegetable or animal products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12425073 | 2012-04-18 | ||
| US201261672931P | 2012-07-18 | 2012-07-18 | |
| PCT/EP2013/057729 WO2013156413A1 (en) | 2012-04-18 | 2013-04-12 | Methods of treating lactose intolerance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ631049A true NZ631049A (en) | 2017-02-24 |
Family
ID=49382950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ631049A NZ631049A (en) | 2012-04-18 | 2013-04-12 | Methods of treating lactose intolerance |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9682050B2 (enExample) |
| EP (1) | EP2844242A1 (enExample) |
| JP (1) | JP6211589B2 (enExample) |
| KR (1) | KR20150002819A (enExample) |
| CN (1) | CN104284655B (enExample) |
| AU (1) | AU2013248397A1 (enExample) |
| BR (1) | BR112014026160A2 (enExample) |
| CA (1) | CA2870490A1 (enExample) |
| EA (1) | EA201491894A1 (enExample) |
| IN (1) | IN2014DN08157A (enExample) |
| MX (1) | MX2014012652A (enExample) |
| NZ (1) | NZ631049A (enExample) |
| WO (1) | WO2013156413A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20050389A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| UA107562C2 (uk) | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
| EP3744398A1 (en) | 2009-02-16 | 2020-12-02 | Nogra Pharma Limited | Alkylamido compounds and uses thereof |
| AU2013217933B2 (en) | 2012-02-09 | 2017-11-30 | Nogra Pharma Limited | Methods of treating fibrosis |
| NZ631049A (en) | 2012-04-18 | 2017-02-24 | Nogra Pharma Ltd | Methods of treating lactose intolerance |
| DK2895160T3 (en) * | 2012-09-13 | 2018-06-25 | Nogra Pharma Ltd | METHODS OF TREATING HAIR-RELATED CONDITIONS |
| MA43682A (fr) * | 2016-02-26 | 2018-11-28 | Nogra Pharma Ltd | Procédés de traitement de l'intolérance au lactose |
| CN107779454A (zh) * | 2016-08-31 | 2018-03-09 | 上海米络凯生物科技有限公司 | 基于PPARγ信号通路的药物筛选模型的构建和应用 |
| PT3921299T (pt) * | 2019-02-08 | 2025-02-17 | Nogra Pharma Ltd | Processo de fabrico do ácido 3-(4'-aminofenil)-2- metoxipropiónico, bem como dos seus análogos e intermediários |
| CN118243646B (zh) * | 2024-04-24 | 2025-01-24 | 武汉简为医疗科技有限公司 | 一种乳糖不耐受检测试剂盒及其使用方法 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB767788A (en) | 1953-12-28 | 1957-02-06 | Schering Corp | Polyiodinated phenyl fatty acid compounds and process for their manufacture |
| US3211610A (en) | 1961-09-29 | 1965-10-12 | Merck & Co Inc | Benzoic acid ester derivatives for treating coccidiosis and method of using same |
| US3444232A (en) | 1966-05-18 | 1969-05-13 | Squibb & Sons Inc | O-alkyl or phenylalkyl benzohydroxamic acids |
| GB1359560A (en) | 1972-02-25 | 1974-07-10 | Merck & Co Inc | Preparation of pyrrylsalicylic acid |
| US4036951A (en) | 1973-03-12 | 1977-07-19 | Synergistics, Inc. | Ultra-violet filtration with certain aminosalicylic acid esters |
| FR2440353A1 (fr) | 1978-11-03 | 1980-05-30 | Science Union & Cie | Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament |
| US4348223A (en) | 1980-12-05 | 1982-09-07 | Ppg Industries, Inc. | N-Alkyl-N-[3-(alkoxyalkyl)phenyl]-2-haloacetamide herbicides |
| DE3164618D1 (en) | 1980-12-22 | 1984-08-09 | Schering Ag | 3-substituted 2,4,6-trihalogenobenzamides and their salts, their preparation and their use as substitutes for natural sweetening agents, and sweeteners containing them |
| JPS58194814A (ja) | 1982-05-11 | 1983-11-12 | Nippon Shinyaku Co Ltd | 免疫調節作用を有する薬剤 |
| IL69282A (en) | 1982-09-02 | 1988-06-30 | Euro Celtique Sa | Method for the carboxylation of potassium phenoxide with carbon dioxide |
| EP0279096B1 (en) | 1987-02-05 | 1993-07-07 | Kureha Kagaku Kogyo Kabushiki Kaisha | Benzyl ether compound and process for producing the same |
| NZ224087A (en) | 1987-04-01 | 1990-08-28 | Dak Lab As | Topical pharmaceutical compositions containing 4- or 5- amino salicylic acid or a functional derivative thereof |
| ES2065980T3 (es) | 1988-05-05 | 1995-03-01 | Tillotts Pharma Ag | Uso del acido 5-aminosalicilico en el tratamiento de alteraciones dermatologicas. |
| US5519014A (en) | 1990-10-22 | 1996-05-21 | Borody; Thomas J. | Treatment of non-inflammatory and non-infectious bowel disorders |
| CA2090220C (en) | 1990-10-22 | 2003-07-08 | Thomas Julius Borody | Treatment of non-inflammatory and non-infectious bowel disorders |
| US5262549A (en) | 1991-05-30 | 1993-11-16 | Polaroid Corporation | Benzpyrylium dyes, and processes for their preparation and use |
| US5302751A (en) | 1992-01-21 | 1994-04-12 | Ethyl Corporation | Profen resolution |
| CA2120367C (en) | 1992-06-30 | 2004-05-11 | Howard K. Shapiro | Compositions and use of pharmaceutical compositions in the treatment of symptoms of disorders related to chronic inflammatory diseases and etiologically related symptomology |
| US5594151A (en) | 1994-01-28 | 1997-01-14 | Prolinx, Inc. | Phenylboronic acid complexing reagents derived from aminosalicylic acid |
| WO1995031194A1 (en) | 1994-05-11 | 1995-11-23 | Shapiro Howard K | Compositions for treatment of chronic inflammatory diseases |
| US5594015A (en) | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
| AU5397496A (en) | 1995-03-28 | 1996-10-16 | Janssen Pharmaceutica N.V. | Low dose ridogrel formulations and their use for the treatme nt of inflammatory bowel diseases |
| GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
| GB9617001D0 (en) | 1996-08-13 | 1996-09-25 | Tillotts Pharma Ag | Oral composition |
| DE19647582A1 (de) | 1996-11-18 | 1998-05-20 | Hoechst Ag | Verfahren zur Herstellung von aromatischen Olefinen mittels Katalyse durch Palladaphosphacyclobutane |
| AU6773598A (en) | 1997-03-26 | 1998-10-20 | Institut Pasteur | Treatment of gastrointestinal disease with ppar modulators |
| WO1999005161A1 (en) | 1997-07-25 | 1999-02-04 | Ligand Pharmaceuticals Incorporated | HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR |
| WO1999015520A1 (en) | 1997-09-19 | 1999-04-01 | Ono Pharmaceutical Co., Ltd. | Fused or nonfused benzene compounds |
| FR2773075B1 (fr) | 1997-12-31 | 2000-05-05 | Cird Galderma | Utilisation d'activateurs de ppar-gamma en dermatologie |
| US6114382A (en) | 1998-11-11 | 2000-09-05 | Moretti; Itagiba G. | Methods for treating inflammatory bowel disease |
| US6326364B1 (en) | 1999-02-08 | 2001-12-04 | Cedars-Sinai Medical Center | Use of 5-aminosalicylates as antimicrobial agents |
| FR2791671B1 (fr) | 1999-04-01 | 2001-05-11 | Oreal | Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation |
| GB9908647D0 (en) | 1999-04-15 | 1999-06-09 | Smithkline Beecham Plc | Novel compounds |
| US20040034067A1 (en) | 1999-04-15 | 2004-02-19 | Macphee Colin Houston | Novel method of treatment |
| GB9914371D0 (en) | 1999-06-18 | 1999-08-18 | Smithkline Beecham Plc | Novel compounds |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| AU2000241494B2 (en) | 2000-04-19 | 2005-03-17 | Gnt Pharma Co., Ltd. | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system |
| CA2410647C (en) | 2000-05-29 | 2010-02-09 | Kyorin Pharmaceutical Co., Ltd. | Substituted phenylpropanoic acid derivatives |
| AU2001285311B2 (en) | 2000-08-29 | 2005-09-15 | Biocon, Ltd | Immunoregulatory compounds, derivatives thereof and their use |
| WO2002046161A1 (en) | 2000-12-05 | 2002-06-13 | Kyorin Pharmaceutical Co., Ltd. | Substituted carboxylic acid derivatives |
| FR2822955B1 (fr) | 2001-03-27 | 2003-10-03 | Chru Lille | Methode de diagnostic de maladies inflammatoires chroniques de l'intestin |
| WO2002085123A1 (en) | 2001-04-18 | 2002-10-31 | Merck & Co., Inc. | Ppar-alpha-gamma ligands or agonists for the treatment of inflammation |
| CA2354921A1 (en) | 2001-05-24 | 2002-11-24 | Yasuo Konishi | Drug evolution: drug design at hot spots |
| HRP20040349A2 (en) | 2001-10-16 | 2005-06-30 | Dr. Reddy's Laboratories Limited | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them |
| GB0127916D0 (en) | 2001-11-21 | 2002-01-16 | Rowett Res Inst | Method |
| UA82835C2 (en) | 2001-12-03 | 2008-05-26 | Reddys Lab Ltd Dr | ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon |
| US20030113815A1 (en) | 2001-12-19 | 2003-06-19 | Pfizer Inc. | Canine peroxisome proliferator activated receptor gamma |
| US20030220374A1 (en) | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
| US20040115127A1 (en) | 2002-04-12 | 2004-06-17 | Wright Samuel D. | Ppar-alpha-gamma ligands or agonists for the treatment of inflammation |
| US20060159648A1 (en) | 2003-02-17 | 2006-07-20 | Davis Adrian F | Novel therapeutic method and compositions for topical administration |
| GB0303609D0 (en) | 2003-02-17 | 2003-03-19 | Glaxo Group Ltd | Novel therapeutic method and compositions |
| WO2004082715A1 (ja) | 2003-03-20 | 2004-09-30 | Eisai Co., Ltd. | 炎症性腸疾患治療剤としての併用医薬 |
| US7589232B2 (en) | 2003-07-21 | 2009-09-15 | Laboratories Serono S.A. | Alkynyl aryl carboxamides |
| JP2007509180A (ja) | 2003-10-21 | 2007-04-12 | インスパイアー ファーマシューティカルズ，インコーポレイティド | 疼痛を治療するための、非ヌクレオチド組成物および方法 |
| WO2005040102A2 (en) | 2003-10-28 | 2005-05-06 | Dr. Reddy's Laboratories Ltd. | Novel compounds and their use as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them |
| JP2007513173A (ja) | 2003-12-03 | 2007-05-24 | スミスクライン・ビーチャム・コーポレイション | ロシグリタゾンを用いる乾癬の治療 |
| CA2553775A1 (en) | 2004-01-20 | 2005-08-11 | Richard F. Harty | Compositions and methods of treatment for inflammatory diseases |
| WO2005084658A1 (en) | 2004-03-04 | 2005-09-15 | Arakis Ltd. | Derivatives of actarit and their therapeutic use |
| US20060286046A1 (en) | 2005-01-05 | 2006-12-21 | Haber C Andrew | Skin care compositions |
| US20060270635A1 (en) | 2005-05-27 | 2006-11-30 | Wallace John L | Derivatives of 4- or 5-aminosalicylic acid |
| ITRM20050390A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| ITRM20050389A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| DE102005061472A1 (de) | 2005-12-22 | 2007-07-05 | Saltigo Gmbh | Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren |
| WO2007096148A1 (en) * | 2006-02-23 | 2007-08-30 | Lipid Nutrition B.V. | Immunoregulation |
| US7645801B2 (en) | 2007-01-29 | 2010-01-12 | Alaven Pharmaceutical Llc | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) |
| IE20070129A1 (en) * | 2007-02-28 | 2008-12-24 | Giuliani Int Ltd | Ppar-gamma agonists stimulate enteric defensin expression |
| ITMI20072429A1 (it) | 2007-12-24 | 2009-06-25 | Giuliani Int Ltd | Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca |
| US8030520B2 (en) | 2008-03-31 | 2011-10-04 | Saltigo Gmbh | Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide |
| UA107562C2 (uk) | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
| EP3744398A1 (en) | 2009-02-16 | 2020-12-02 | Nogra Pharma Limited | Alkylamido compounds and uses thereof |
| EP2298321A1 (en) | 2009-08-26 | 2011-03-23 | Nordic Pharma | Novel pharmaceutical compositions for treating IBD |
| US20140256661A1 (en) | 2011-07-15 | 2014-09-11 | David Nigel Armstrong | Pharmaceutical compositions for rectal administration |
| AU2013217933B2 (en) | 2012-02-09 | 2017-11-30 | Nogra Pharma Limited | Methods of treating fibrosis |
| NZ631049A (en) | 2012-04-18 | 2017-02-24 | Nogra Pharma Ltd | Methods of treating lactose intolerance |
| BR112014030039A2 (pt) | 2012-06-01 | 2017-06-27 | Nogra Pharma Ltd | heterociclos bicíclicos capazes de modular respostas de células t e métodos de uso dos mesmos |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| DK2895160T3 (en) | 2012-09-13 | 2018-06-25 | Nogra Pharma Ltd | METHODS OF TREATING HAIR-RELATED CONDITIONS |
| EP2897603A1 (en) | 2012-09-13 | 2015-07-29 | Nogra Pharma Limited | Methods of inhibiting hair growth |
-
2013
- 2013-04-12 NZ NZ631049A patent/NZ631049A/en not_active IP Right Cessation
- 2013-04-12 AU AU2013248397A patent/AU2013248397A1/en not_active Abandoned
- 2013-04-12 BR BR112014026160A patent/BR112014026160A2/pt not_active IP Right Cessation
- 2013-04-12 CA CA2870490A patent/CA2870490A1/en not_active Abandoned
- 2013-04-12 IN IN8157DEN2014 patent/IN2014DN08157A/en unknown
- 2013-04-12 EP EP13715249.2A patent/EP2844242A1/en not_active Withdrawn
- 2013-04-12 WO PCT/EP2013/057729 patent/WO2013156413A1/en not_active Ceased
- 2013-04-12 JP JP2015506193A patent/JP6211589B2/ja not_active Expired - Fee Related
- 2013-04-12 EA EA201491894A patent/EA201491894A1/ru unknown
- 2013-04-12 CN CN201380020479.9A patent/CN104284655B/zh not_active Expired - Fee Related
- 2013-04-12 US US14/394,916 patent/US9682050B2/en not_active Expired - Fee Related
- 2013-04-12 MX MX2014012652A patent/MX2014012652A/es unknown
- 2013-04-12 KR KR1020147031925A patent/KR20150002819A/ko not_active Withdrawn
-
2017
- 2017-05-12 US US15/594,023 patent/US20180064667A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015518483A (ja) | 2015-07-02 |
| KR20150002819A (ko) | 2015-01-07 |
| CN104284655A (zh) | 2015-01-14 |
| WO2013156413A1 (en) | 2013-10-24 |
| BR112014026160A2 (pt) | 2017-07-18 |
| US20180064667A1 (en) | 2018-03-08 |
| CN104284655B (zh) | 2017-10-27 |
| US9682050B2 (en) | 2017-06-20 |
| AU2013248397A1 (en) | 2014-10-02 |
| CA2870490A1 (en) | 2013-10-24 |
| US20150087678A1 (en) | 2015-03-26 |
| MX2014012652A (es) | 2014-11-25 |
| EP2844242A1 (en) | 2015-03-11 |
| IN2014DN08157A (enExample) | 2015-05-01 |
| JP6211589B2 (ja) | 2017-10-11 |
| EA201491894A1 (ru) | 2015-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ631049A (en) | Methods of treating lactose intolerance | |
| ZA202004764B (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
| MD3240554T2 (ro) | Blautia stercosis și wexlerae pentru utilizare în tratarea bolilor inflamatorii și autoimune | |
| ZA201906100B (en) | Combination of a ppar agonist with a fxr agonist | |
| WO2014138429A3 (en) | Peptidomimetic macrocycles and use thereof in regulating hif1alpha | |
| IL252943A0 (en) | Sunitinib formulations and methods of using them for the treatment of eye diseases | |
| MX2016012021A (es) | Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. | |
| TN2015000434A1 (en) | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | |
| MY169328A (en) | Compositions for the treatment of dry eye | |
| TWD185135S (zh) | 超音波裝置 | |
| MX2019002669A (es) | Composicion farmaceutica para usarse en el tratamiento de la malnutricion en un sujeto que exhibe un trastorno de espectro de autismo (asd). | |
| TWD177508S (zh) | 超音波裝置 | |
| IN2014CN04014A (enExample) | ||
| PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| PH12017502224A1 (en) | Positive allosteric modulators of muscarinic md receptor | |
| PH12014500250A1 (en) | Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| MX2016008150A (es) | Formulaciones de berberina y usos de las mismas. | |
| TWD175951S (zh) | 護理床和醫院病床的操作單元 | |
| MX2016003293A (es) | Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados. | |
| MX2013010367A (es) | Composiciones y metodos para la terapia y diagnostico de influenza. | |
| PH12015500322B1 (en) | Tris(hetero)arylpyrazoles and use thereof | |
| MX369774B (es) | Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos. | |
| GB201115977D0 (en) | Neurodevelopmental disorders | |
| PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 APR 2020 BY COMPUTER PACKAGES INC Effective date: 20170531 |
|
| LAPS | Patent lapsed |